The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    August 2016

  • Pages
    228

  • View Count
    1646

Example Insights

  1. Glaucoma is the second leading cause of blindness, worldwide, after cataract. It is estimated that, by 2020, around 79.6 million people in the world will have glaucoma. Specifically, in the US, it is estimated that, by 2020, 4 million people will have glaucoma with 50% cases left undiagnosed.
  2. Currently available treatment options (ocular hypotensive medications, laser therapy and surgical interventions) are associated with a number of complications and adverse events. Known drawbacks include poor patient compliance, loss of adequate response, intolerable ocular and systemic adverse effects, and degradation of quality of life.
  3. Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors, adenosine receptor agonists, adenosine A3 receptor antagonists and Nitric oxide (NO) donors have emerged as novel drug classes in this field. In fact, one drug (Glanatec from Kowa Company) is already available in the Japanese market; more than 20 are in clinical development and rest are in the preclinical / discovery phase. 
  4. Examples of players with candidate molecules in the late stages development include Aerie Pharmaceuticals (Rhopressa™ and Roclatan™), Inotek Pharmaceuticals (Trabodenoson), Santen Pharmaceutical (DE-117) and Valeant Pharmaceuticals (Vesneo™). In addition, a number of other start-ups are exploring the potential in this domain.
  5. 13 novel drug delivery devices are under development as sustained release systems. Specifically, Bimatoprost SRfrom Allergan is already in Phase III of clinical development. A number of other devices, currently in early stages of development, are likely to provide a credible alternative to tackle the challenges associated with poor patient compliance.
  6. Advances in glaucoma surgery have led to the emergence of several novel surgical devices. There are over 30 novel surgical devices that have been developed / are being developed for the treatment of elevatedIOP. MIGS devices currently represent a growing portion of the glaucoma surgery market; these have been shown to provide better results compared to traditional trabeculectomy procedures.
  7. Over the course of next ten years, the market for novel drugs is likely to grow at a relatively higher annualized rate of 83.9%. Similarly, we expect significant growth in the market of sustained release drug delivery devices and novel surgical devices. Combined, such novel drugs and devices are expected to cater to over 65% of the total glaucoma market by 2026.   

Overview

An imbalance in the production and / or drainage of aqueous humor within the eye is known to lead to an increase in intraocular pressure (IOP). Acutely elevated IOP, a condition broadly known as ocular hypertension, may either lead to the expulsion of ocular contents through a traumatic opening or result in a number of clinical conditions / disorders including glaucoma. Currently available treatment options include ocular hypotensive medications, laser therapy and surgical interventions. However, these treatment modalities are known to be associated with a number of complications and adverse events. Amongst these, poor adherence rates are a major concern in patients who are on ocular hypotensive medications; an estimated 50% of patients do not adhere to the therapeutic regimen prescribed to them. Laser therapies are known to lose their efficacy over time. It has been observed that the disease is controlled only in around 50% of patients who have been treated with some form of laser therapy; the effect usually wears off after a period of five years. Traditional surgical procedures, such as filtration procedures, glaucoma drainage devices (GDDs) and cyclodestructive procedures, are also known to have various risks and complications associated with them. Therefore, in the current scenario, multiple challenges exist as far as the treatment of elevated IOP is concerned.

A better understanding of the complex pathways involved in aqueous humor dynamics has resulted in the identification of many novel targets for maintaining ocular homeostasis. These novel targets have led to the development of a number of innovative therapeutic options for lowering elevated IOP. Specifically, to address poor patient compliance, a number of players are developing sustained release devices (implants, punctal plugs or contact lenses) so that the patient is not required to self-medicate on a regular basis. Similarly, the landscape of surgical interventions is also witnessing a lot of change with the emergence of safer, reproducible and less invasive treatment options. These novel surgical interventions include minimally-invasive glaucoma surgery (MIGS), blebless ab externo glaucoma surgery (BAGS), ab externo bleb surgery (ABS), minimally invasive micro sclerostomy (MIMS), non-penetrating glaucoma surgery (NPGS) and non-invasive glaucoma procedure (NIGP).

 

Scope of the Report

The ‘Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026’ report provides an extensive study of the emerging market of such novel drugs, devices and surgical procedures for the treatment of elevated IOP. The focus of this study is on the applications of these novel treatment options, both marketed and under development, and their likely mid to long term evolution. These treatment options claim to provide consistent benefits related to IOP lowering and are anticipated to gain widespread adoption in the foreseen future.

The report covers various aspects of this market; some of these are outlined below:

  • A detailed assessment of the current market landscape of novel drugs and devices, key players involved, the status of development of various pipeline products and the target patient segments.
  • Comprehensive profiles covering mechanism of action, clinical trial details and associated developments of Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors and NO donating prostaglandins in late stage of development.
  • Comprehensive profiles highlighting the IOP reduction approach, key performance drivers, safety and efficacy of novel surgical procedures that have been approved or are in advanced stages of development.
  • Comparative analysis of MIGS devices based on various parameters such as drainage route, length of the implant, involvement of conjunctiva, type of procedure (ab interno or ab externo), procedure duration and ability of the device to treat 360 degrees.
  • An informed view on the likely future evolution of such novel drugs, sustained release drug delivery devices and surgical procedures over the next decade. This includes sales forecasts of six novel drugs, including Rhopressa, Roclatan and Vesneo. Similarly, we have presented our view on the future market size of six drug delivery devices, including Bimatoprost SR, OTX-TP and punctal plug delivery system. We have also determined the likely future revenues for MIGS and non-MIGS surgical devices (BAGS, ABS, NIGP and NPGS).  

To account for the uncertainties in the market, we have provided three market forecast scenarios that represent three different tracks of the market’s evolution. Given the current unmet need for safer and more effective therapeutic options and the rich pipeline of novel drugs and devices, we expect this market to witness significant growth in the coming few years.

Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).

Contents

Chapter 2  provides an executive summary and offers a high level view on where the market for IOP lowering novel drugs and devices is headed in the mid to long term.

Chapter 3  is a general introduction to IOP and the various diseases associated with elevated IOP. It contains detailed discussions on aqueous humor dynamics and the various factors responsible for an increase in IOP. The chapter also outlines the currently available treatment modalities for IOP related diseases and their shortcomings.

Chapter 4  includes information on novel drugs that are either already available or being evaluated in different stages of development for the treatment of IOP. In this chapter, we have presented a comprehensive pipeline of all such products that we identified during our research. It presents an analysis of the aforementioned pipeline based on a number of different parameters, including phase of development, mechanism of action, disease sub-type, route of administration and dosage schedule.

Chapter 5  presents information on the various types of novel devices (surgical and drug delivery devices) that are either already available in the market or being evaluated in different stages of development. Similar to the previous chapter, we have presented a comprehensive pipeline of all relevant devices that we came across during our research. The chapter provides an analysis of the pipeline based on the phase of development of the product, its purpose, the category of devices it belongs to and the approach / pathway it employs for IOP reduction. In addition, we have added a separate section on drug delivery devices highlighting details such as the type of drug delivered and the nature of implant (biodegradable or non-biodegradable).

Chapter 6  provides detailed company profiles of the prominent players that are involved in investigating novel drugs for the treatment of elevated IOP. Each company profile includes a brief overview of the company, its financial information, key performance drivers, and its future outlook and strategy. In addition, the profiles cover details of late stage candidate therapies, such as Rho-associated protein kinase (ROCK) inhibitors, ROCK / norepinephrine transporter (NET) inhibitors and NO donating prostaglandins, which are being evaluated for the treatment of elevated IOP. These details include an overview of the product, its mechanism of action, collaborations / partnerships specific to the particular drug, key developmental events and the associated clinical trials landscape.

Chapter 7  provides details on some of the important players involved in the development of MIGS and BAGS devices. Each company profile includes a brief overview of the company, funding instances,financial information, key performance drivers, and its future outlook and strategy. In addition, the profiles cover details of company’s approved / clinical stage devices.  These details include a brief overview of the product, its specifications (size, shape, material and surgical procedure used to insert the device into the eye), the IOP reduction approach it follows, details of its clinical studies, and efficacy and safety data.

Chapter   8  offers a comprehensive perspective on how the market for novel drugs and devices in this field is likely to evolve over the next ten years. In this chapter, we have forecasted the sales of six novel drugs, including Rhopressa, Roclatan and Vesneo. Similarly, we have presented our view on the future market size of six drug delivery devices, which include Bimatoprost SR, OTX-TP and punctal plug delivery system. We have also determined the likely future revenues for MIGS and non-MIGS devices (BAGS, ABS, NIGP and NPGS). Due to uncertainties surrounding some of the key assumptions made within our forecast model, we have presented three different evolutionary scenarios for the overall market, namely the base, conservative and optimistic scenarios.

Chapter 9  provides information on MIGS devices covering the salient features that distinguish them from traditional surgical interventions. The chapter includes an overview of the current market landscape of MIGS devices and presents an approval timeline highlighting all the approved devices of this nature. We have also presented a comparative spider web analysis of MIGS devices (for both approved and under development devices) based on different parameters, such as drainage route, length of the implant, involvement of conjunctiva, type of procedure (ab interno or ab externo), duration of the procedure, the ability to treat entire Schlemm’s canal and the target patient segment.

Chapter 10  summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion regarding the market based on the research and analysis described in the previous chapters.

Chapter 11  is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).

Chapters 12 and 13  are appendices, which provide tabulated data and a list of companies that are mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Overview
3.2. Structure of the Eye
3.3. Aqueous Humor Dynamics
3.3.1. Aqueous Humor Production
3.3.2. Aqueous Humor Drainage
3.4. Factors Responsible for Elevated IOP
3.5. Diseases Associated with Elevated IOP
3.5.1. Ocular Hypertension
3.5.2. Glaucoma
3.5.3. Retinal Artery Occlusion
3.6. Treatment Options: Ocular Hypertension and Glaucoma
3.6.1. Medical Treatment
3.6.2. Laser Therapy
3.6.2.1. Argon Laser Trabeculoplasty (ALT)
3.6.2.2. Selective Laser Trabeculoplasty (SLT)
3.6.3. Surgical Treatment
3.7. Drawbacks of Currently Available Treatment Options
3.7.1. Drawbacks of Medical Treatment
3.7.2. Drawbacks of Laser Therapy
3.7.3. Drawbacks of Surgical Treatment
3.8. Novel Therapeutic Targets for Lowering IOP
3.9. Novel Devices for Lowering IOP
3.9.1. Novel Surgical Devices
3.9.2. Novel Sustained Release Drug Delivery Devices
 
4. MARKET LANDSCAPE: NOVEL DRUGS
4.1. Chapter Overview and Scope
4.2. Novel Drugs to Treat Elevated IOP: Clinical and Preclinical Pipeline
4.2.1. Novel Drugs to Treat Elevated IOP: Analysis by Highest Phase of Development
4.2.2. Novel Drugs to Treat Elevated IOP: Analysis by Mechanism of Action
4.2.3. Novel Drugs to Treat Elevated IOP: Analysis by Disease Sub-type
4.2.4. Novel Drugs to Treat Elevated IOP: Analysis by Route of Administration
4.2.5. Novel Drugs to Treat Elevated IOP: Analysis by Dosing Schedule
 
5. MARKET LANDSCAPE: NOVEL DEVICES
5.1. Chapter Overview
5.2. Novel Devices to Treat Elevated IOP: Pipeline Analysis
5.2.1. Novel Devices to Treat Elevated IOP: Analysis by Highest Phase of Development
5.2.2. Novel Devices to Treat Elevated IOP: Analysis by Purpose of the Device
5.2.3. Novel Devices to Treat Elevated IOP: Analysis by Category of the Device
5.2.4. Novel Devices to Treat Elevated IOP: Analysis by Approach / Pathway for IOP Reduction
5.2.5. Sustained Release Drug Delivery Devices
 
6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Aerie Pharmaceuticals
6.2.1. Company Overview
6.2.2. Funding
6.2.3. Future Outlook
6.2.4. Product Profile: Rhopressa™ (AR-13224 / Netarsudil Mesylate)
6.2.4.1. Drug Specification
6.2.4.2. Mechanism of Action
6.2.4.3. Key Development Events
6.2.5. Product Profile: Roclatan™ (PG324)
6.2.5.1. Drug Specification
6.2.5.2. Mechanism of Action
6.2.5.3. Key Development Events
 
6.3. Inotek Pharmaceuticals
6.3.1. Company Overview
6.3.2. Funding
6.3.3. Future Outlook
6.3.4. Product Profile: Trabodenoson (INO-8875)
6.3.4.1. Drug Specification
6.3.4.2. Mechanism of Action
6.3.4.3. Key Development Events
 
6.4. Kowa Company
6.4.1. Company Overview
6.4.2. Future Outlook
6.4.3. Product Profile: Glanatec™ (Ripasudil / K-115)
6.4.3.1. Drug Specification
6.4.3.2. Mechanism of Action
6.4.3.3. Collaboration with D. Western Therapeutics Institute
6.4.3.4. Key Development Events
 
6.5. Santen Pharmaceutical
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Future Outlook
6.5.4. Product Profile: DE-117
6.5.4.1. Drug Specification
6.5.4.2. Mechanism of Action
6.5.4.3. Collaboration with Ube Industries
6.5.4.4. Key Development Events
6.5.5. Product Profile: Sepetaprost (ONO-9054 / DE-126)
6.5.5.1. Drug Specification
6.5.5.2. Mechanism of Action
6.5.5.3. Collaboration with Ono Pharmaceutical
6.5.5.4. Key Development Events
 
6.6. Valeant Pharmaceuticals International
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Future Outlook
6.6.4. Product Profile: Vesneo™ (Latanoprostene Bunod)
6.6.4.1. Drug Specification
6.6.4.2. Mechanism of Action
6.6.4.3. Collaboration with NicOx
6.6.4.4. Key Development Events
 
7. COMPANY AND DEVICE PROFILES
7.1. Chapter Overview
7.2. Alcon (a Novartis Company)
7.2.1. Company Overview
7.2.2. Acquisition of Transcend Medical
7.2.3. Financial Information
7.2.4. Future Outlook
7.2.5. CyPass® Micro-Stent
7.2.5.1. Product Overview
7.2.5.2. IOP Reduction Approach
7.2.5.3. Product Specifications
7.2.5.4. Key Development Events
7.2.5.5. Clinical Studies
7.2.5.6. Key Clinical Results
 
7.3. Allergan
7.3.1. Company Overview
7.3.2. Acquisition of AqueSys
7.3.3. Financial Information
7.3.4. Future Outlook
7.3.5. XEN™ Gel Stent
7.3.5.1. Product Overview
7.3.5.2. IOP Reduction Approach
7.3.5.3. Product Specifications
7.3.5.4. Clinical Studies
7.3.5.5. Key Clinical Results
 
7.4. Ellex
7.4.1. Company Overview
7.4.2. Acquisition of Canaloplasty Business of iScience Interventional
7.4.3. Financial Information
7.4.4. Future Outlook
7.4.5. iTrack™ 250A (to Perform Traditional Canaloplasty)
7.4.5.1. Product Overview
7.4.5.2. IOP Reduction Approach
7.4.5.3. Product Specifications
7.4.5.4. Key Clinical Results
7.4.6. iTrack™ 250A (to Perform ABiC)
7.4.6.1. Product Overview
7.4.6.2. Approach of IOP Reduction
7.4.6.3. Product Specifications
7.4.6.4. Key Clinical Results
 
7.5. Glaukos
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Future Outlook
7.5.4. iStent®
7.5.4.1. Product Overview
7.5.4.2. IOP Reduction Approach
7.5.4.3. Product Specifications
7.5.4.4. Key Development Events
7.5.4.5. Clinical Studies
7.5.4.6. Key Clinical Results
7.5.5. iStent inject®
7.5.5.1. Product Overview
7.5.5.2. IOP Reduction Approach
7.5.5.3. Product Specifications
7.5.5.4. Key Development Events
7.5.5.5. Clinical Studies
7.5.5.6. Key Clinical Results
7.5.6. iStent Supra®
7.5.6.1. Product Overview
7.5.6.2. IOP Reduction Approach
7.5.6.3. Product Specifications
7.5.6.4. Key Development Events
7.5.6.5. Clinical Studies
7.5.6.6. Key Clinical Results
 
7.6. InnFocus
7.6.1. Company Overview
7.6.2. Funding
7.6.3. Future Outlook
7.6.4. InnFocus Microshunt™
7.6.4.1. Product Overview
7.6.4.2. IOP Reduction Approach
7.6.4.3. Product Specifications
7.6.4.4. Key Development Events
7.6.4.5. Clinical Studies
7.6.4.6. Key Clinical Results
 
7.7. iSTAR Medical
7.7.1. Company Overview
7.7.2. Funding
7.7.3. Future Outlook
7.7.4. STARflo™ Glaucoma Implant
7.7.4.1. Product Overview
7.7.4.2. IOP Reduction Approach
7.7.4.3. Product Specifications
7.7.4.4. Key Development Events
7.7.4.5. Regional Collaborations
7.7.4.6. Clinical Studies
 
7.8. Ivantis
7.8.1. Company Overview
7.8.2. Funding
7.8.3. Future Outlook
7.8.4. Hydrus™ Microstent
7.8.4.1. Product Overview
7.8.4.2. IOP Reduction Approach
7.8.4.3. Product Specifications
7.8.4.4. Key Development Events
7.8.4.5. Clinical Studies
7.8.4.6. Key Clinical Results
 
7.9. New World Medical
7.9.1. Company Overview
7.9.2. Future Outlook
7.9.3. Kahook Dual Blade™
7.9.3.1. Product Overview
7.9.3.2. IOP Reduction Approach
7.9.3.3. Product Specifications
 
7.10. Sight Sciences
7.10.1. Company Overview
7.10.2. Funding
7.10.3. Future Outlook
7.10.4. TRAB™360
7.10.4.1. Product Overview
7.10.4.2. IOP Reduction Approach
7.10.4.3. Product Specifications
7.10.4.4. Key Clinical Results
7.10.5. VISCO™360
7.10.5.1. Product Overview
7.10.5.2. IOP Reduction Approach
7.10.5.3. Product Specifications
 
8. MARKET FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology and Assumptions
8.3. Overall Glaucoma Market, 2016 – 2026
8.3.1. Novel Drugs Market, 2016 – 2026
8.3.1.1. Glanatec™ (Ripasudil / K-115): Sales Forecast
8.3.1.2. Vesneo™ (Latanoprostene bunod): Sales Forecast
8.3.1.3. Rhopressa™ (AR-13224 / Netarsudil Mesylate): Sales Forecast
8.3.1.4. Trabodenoson (INO-8875): Sales Forecast
8.3.1.5. Roclatan™ (PG324): Sales Forecast
8.3.1.6. DE-117: Sales Forecast
 
8.3.2. Sustained Release Drug Delivery Devices Market
8.3.2.1. Bimatoprost SR: Sales Forecast
8.3.2.2. Helios™ Insert(Bimatoprost Ring): Sales Forecast
8.3.2.3. Punctal Plug Delivery System Sales Forecast
8.3.2.4. ENV 515: Sales Forecast
8.3.2.5. OTX-TP: Sales Forecast
8.3.2.6. iDose™: Sales Forecast
 
8.3.3. Novel Surgical Devices Market, 2016 – 2026
8.3.3.1. MIGS Devices: Sales Forecast, 2016 – 2026
8.3.3.2. Non-MIGS Devices: Sales Forecast, 2016 – 2026
 
9. MIGS DEVICES: COMPARATIVE SPIDER WEB ANALYSIS
9.1. Chapter Overview
9.2. MIGS Devices: An Overview
9.3. MIGS Devices: Approval Timeline
9.4. MIGS Devices: Competitive landscape
9.5. Comparative Analysis of MIGS Devices
9.5.1. Comparative Analysis of Implants
9.5.2. Comparative Analysis of Ablation Devices
 
10. CONCLUSION
10.1. Novel Drug Classes have Recently Emerged for the Management of IOP
10.2. Sustained Release Devices are Expected to Eradicate Compliance Issues
10.3. Microinvasive Surgery has the Potential to Revolutionize Glaucoma Treatment
10.4. Significant Shift is Likely to Occur in the Overall Market Landscape in the Mid-Long Term
10.5. Concluding Remarks
 
11. INTERVIEW TRANSCRIPTS
11.1. Chapter Overview
11.2. Bob Butchofsky, Founder and CEO, Mati Therapeutics
11.3. Donald Schwartz, CEO and President, Eye Sonix
11.4. Ronen Castro, CEO, IOPtima
11.5. Suzana Nahum Zilberberg, CEO, Bio-Light Life Sciences
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Novel Surgical Devices: Approaches for IOP Reduction
Figure 4.1  Novel Drugs to Treat Elevated IOP: Distribution by Highest Phase of Development
Figure 4.2  Novel Drugs to Treat Elevated IOP: Distribution by Mechanism of Action
Figure 4.3  Novel Drugs to Treat Elevated IOP: Distribution by Disease Sub-type
Figure 4.4  Novel Drugs to Treat Elevated IOP: Distribution by Route of administration
Figure 4.5  Novel Drugs to Treat Elevated IOP: Distribution by Dosing Schedule
Figure 5.1  Novel Devices to Treat Elevated IOP: Distribution by Highest Phase of Development
Figure 5.2  Novel Devices to Treat Elevated IOP: Approved Products in the US and EU
Figure 5.3  Novel Devices to Treat Elevated IOP: Distribution by Purpose of the Device
Figure 5.4  Novel Devices to Treat Elevated IOP: Distribution by Category of the Device
Figure 5.5  Novel Devices to Treat Elevated IOP: Distribution by Approach / Pathway for IOP Reduction
Figure 6.1  Rhopressa™: Clinical Development Timeline
Figure 6.2  Roclatan™: Clinical Development Timeline
Figure 6.3  Trabodenoson: Clinical Development Timeline
Figure 6.4  Glanatec™: Clinical Development Timeline
Figure 6.5  Santen Annual Revenues, FY 2010 – FY 2015 (JPY Billion)
Figure 6.6  DE-117: Clinical Development Timeline
Figure 6.7  Sepetaprost: Clinical Development Timeline
Figure 6.8  Valeant Pharmaceuticals Annual Revenues, 2010 – 2015 (USD Billion)
Figure 6.9  Vesneo™: Clinical Development Timeline
Figure 7.1  Alcon Annual Revenues, 2011 – H1 2016 (USD Billion)
Figure 7.2  Allergan Annual Revenues, 2011– H1 2016 (USD Billion)
Figure 7.3  Ellex Annual Revenues, FY 2011 – FY 2015 (USD Million)
Figure 7.4  Glaukos Annual Revenues, 2013 – H1 2016 (USD Million)
Figure 8.1  Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 – 2026, Base Scenario (USD Billion)
Figure 8.2  Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Base Scenario)
Figure 8.3  Novel Drugs Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.4  Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
Figure 8.5  Vesneo™ (Latanoprostene Bunod) Sales Forecast, 2017 - 2026: Base Scenario (USD Billion)
Figure 8.6  Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Base Scenario (USD Billion)
Figure 8.7  Trabodenoson (INO-8875) Sales Forecast: Base Scenario (USD Billion)
Figure 8.8  Roclatan™ (PG324) Sales Forecast: Base Scenario (USD Billion)
Figure 8.9  DE-117 Sales Forecast: Base Scenario (USD Billion)
Figure 8.10 Sustained Release Devices Sales Forecast: Base Scenario (USD Billion)
Figure 8.11 Bimatoprost SR Sales Forecast: Base Scenario (USD Billion)
Figure 8.12 Helios™ Insert (Bimatoprost Ring) Sales Forecast: Base Scenario (USD Billion)
Figure 8.13 Punctal Plug Delivery System Sales Forecast: Base Scenario (USD Billion)
Figure 8.14 ENV515 Sales Forecast: Base Scenario (USD Billion)
Figure 8.15 OTX-TP Sales Forecast: Base Scenario (USD Billion)
Figure 8.16 iDose™ Sales Forecast: Base Scenario (USD Billion)
Figure 8.17 Novel Surgical Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.18 MIGS Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.19 Non-MIGS Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.20 Non-MIGS Devices Market, 2026: Distribution by Device Category
Figure 9.1  MIGS Devices: Approval Timeline
Figure 9.2  MIGS Devices: Comparative Analysis of Implants
Figure 9.3  MIGS Devices: Comparative Analysis of Ablation Devices
Figure 10.1 Glaucoma Therapies Market: Distribution by Treatment Modalities, 2016, 2021, and 2026 (USD Billion)

List of Tables

Table 3.1   Eye: Description of Tissue Layers
Table 3.2   Currently Available Drugs for Ocular Hypertension and Glaucoma
Table 3.3   Currently Available Fixed Combination Treatments
Table 3.4   Ocular Adverse Reactions by Drug Class
Table 3.5   Systemic Adverse Reactions by Drug Class
Table 3.6   New Therapeutic Targets for Lowering IOP
Table 4.1   Novel Drugs to Treat Elevated IOP: Marketed and Clinical Pipeline
Table 4.2   Novel Drugs to Treat Elevated IOP: Preclinical and Discovery Pipeline
Table 5.1   Novel Devices to Treat Elevated IOP: Pipeline
Table 5.2   Sustained Release Drug Delivery Devices
Table 6.1   Novel Drugs in Advanced Stages of Development
Table 6.2   Aerie Pharmaceuticals: Product Candidates to Treat Elevated IOP
Table 6.3   Kowa’s Pharmaceutical Business Division: Therapeutic Areas and Related Indications
Table 6.4   Santen Pharmaceutical: Novel Product Candidates
Table 7.1   List of Company and Device Profiles
Table 7.2   CyPass® Micro-Stent: Industry Sponsored Clinical Trials
Table 7.3   XEN™ Gel Stent: Industry Sponsored Clinical Trials
Table 7.4   Ellex: Novel IOP Lowering Devices
Table 7.5   Ellex 2015 Sales: Key Market Segments
Table 7.6   Glaukos: IOP Lowering Product Portfolio
Table 7.7   iStent®: Industry Sponsored Clinical Trials
Table 7.8   iStent inject®: Industry Sponsored Clinical Trials
Table 7.9   iStent Supra®: Industry Sponsored Clinical Trials
Table 7.10  InnFocus Microshunt™: Industry Sponsored Clinical Trials
Table 7.11  iSTAR Medical: Devices in Development
Table 7.12  iSTAR Medical: Global Distribution Partners
Table 7.13  Hydrus™ Microstent: Industry Sponsored Clinical Trials
Table 7.14  Sight Sciences: Novel IOP Lowering Devices
Table 8.1   Novel Drugs: Estimated Launch Years
Table 8.2   Sustained Release Drug Delivery Devices: Estimated Launch Years
Table 9.1   MIGS Devices Competitive Landscape
Table 9.2   Comparative Analysis of Implants: Details on Parameters
Table 9.3   Comparative Analysis of Ablation Devices: Details on Parameters
Table 12.1  Novel Drugs to Treat Elevated IOP: Distribution by Highest Phase of Development
Table 12.2  Novel Drugs to Treat Elevated IOP: Distribution by Mechanism of Action
Table 12.3  Novel Drugs to Treat Elevated IOP: Distribution by Disease Sub-type
Table 12.4  Novel Drugs to Treat Elevated IOP: Distribution by Route of administration
Table 12.5  Novel Drugs to Treat Elevated IOP: Distribution by Dosing Schedule
Table 12.6  Novel Devices to Treat Elevated IOP: Distribution by Highest Phase of Development
Table 12.7  Novel Devices: Approved Products in the US and EU
Table 12.8  Novel Devices to Treat Elevated IOP: Distribution by Purpose of the Device
Table 12.9  Novel Devices to Treat Elevated IOP: Distribution by Category of the Device
Table 12.10  Novel Devices to Treat Elevated IOP: Distribution by Approach / Pathway for IOP reduction
Table 12.11 Santen Annual Revenues, FY 2010 – FY 2015 (JPY Billion)
Table 12.12 Valeant Pharmaceuticals Annual Revenues, 2010 – 2015 (USD Billion)
Table 12.13 Alcon Annual Revenues, 2011 – H1 2016 (USD Billion)
Table 12.14 Allergan Annual Revenues, 2011- H1 2016 (USD Billion)
Table 12.15 Ellex Annual Revenues, FY 2011 – FY 2015 (USD Million)
Table 12.16 Glaukos Annual Revenues, 2013 – H1 2016 (USD Million)
Table 12.17 Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 – 2026, Base Scenario (USD Billion)
Table 12.18 Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 – 2026, Optimistic Scenario (USD Billion)
Table 12.19 Overall Glaucoma Market: Distribution by Treatment Modalities, 2016 – 2026, Conservative Scenario (USD Billion)
Table 12.20 Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Base Scenario)
Table 12.21 Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Optimistic Scenario)
Table 12.22 Glaucoma Market: Share of Different Treatment Options 2016, 2021, and 2026 (Conservative Scenario)
Table 12.23 Novel Drugs Market, 2016 – 2026: Base Scenario (USD Billion)
Table 12.24 Novel Drugs Market, 2016 – 2026: Optimistic Scenario (USD Billion)
Table 12.25 Novel Drugs Market, 2016 – 2026: Conservative Scenario (USD Billion)
Table 12.26 Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
Table 12.27 Glanatec™ (Ripasudil / K-115) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.28 Glanatec™ (Ripasudil / K-115) Sales Forecast: Base Scenario (USD Billion)
Table 12.29 Vesneo™ (Latanoprostene bunod) Sales Forecast: Base Scenario (USD Billion)
Table 12.30 Vesneo™ (Latanoprostene bunod) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.31 Vesneo™ (Latanoprostene bunod) Sales Forecast: Conservative Scenario (USD Billion)
Table 12.32 Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Base Scenario (USD Billion)
Table 12.33 Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.34 Rhopressa™ (AR-13224 / Netarsudil Mesylate) Sales Forecast: Conservative Scenario (USD Billion)
Table 12.35 Trabodenoson (INO-8875) Sales Forecast: Base Scenario (USD Billion)
Table 12.36 Trabodenoson (INO-8875) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.37 Trabodenoson (INO-8875) Sales Forecast: Conservative Scenario (USD Billion)
Table 12.38 Roclatan™ (PG324) Sales Forecast: Base Scenario (USD Billion)
Table 12.39 Roclatan™ (PG324) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.40 Roclatan™ (PG324) Sales Forecast: Conservative Scenario (USD Billion)
Table 12.41 DE-117 Sales Forecast: Base Scenario (USD Billion)
Table 12.42 DE-117 Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.43 DE-117 Sales Forecast: Conservative Scenario (USD Billion)
Table 12.44 Sustained Release Devices Sales Forecast: Base Scenario (USD Billion)
Table 12.45 Sustained Release Devices Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.46 Sustained Release Devices Sales Forecast: Conservative Scenario (USD Billion)
Table 12.47 Bimatoprost SR Sales Forecast: Base Scenario (USD Billion)
Table 12.48 Bimatoprost SR Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.49 Bimatoprost SR Sales Forecast: Conservative Scenario (USD Billion)
Table 12.50 Helios™ Insert (Bimatoprost Ring) Sales Forecast: Base Scenario (USD Billion)
Table 12.51 Helios™ Insert (Bimatoprost Ring) Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.52 Helios™ Insert (Bimatoprost Ring) Sales Forecast: Conservative Scenario (USD Billion)
Table 12.53 Punctal Plug Delivery System Sales Forecast: Base Scenario (USD Billion)
Table 12.54 Punctal Plug Delivery System Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.55 Punctal Plug Delivery System Sales Forecast: Conservative Scenario (USD Billion)
Table 12.56 ENV515 Sales Forecast: Base Scenario (USD Billion)
Table 12.57 ENV515 Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.58 ENV515 Sales Forecast: Conservative Scenario (USD Billion)
Table 12.59 OTX-TP Sales Forecast: Base Scenario (USD Billion)
Table 12.60 OTX-TP Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.61 OTX-TP Sales Forecast: Conservative Scenario (USD Billion)
Table 12.62 iDose™ Sales Forecast: Base Scenario (USD Billion)
Table 12.63 iDose™ Sales Forecast: Optimistic Scenario (USD Billion)
Table 12.64 iDose™ Sales Forecast: Conservative Scenario (USD Billion)
Table 12.65 Novel Surgical Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Table 12.66 Novel Surgical Devices Market, 2016 – 2026: Optimistic Scenario (USD Billion)
Table 12.67 Novel Surgical Devices Market, 2016 – 2026: Conservative Scenario (USD Billion)
Table 12.68 MIGS Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Table 12.69 MIGS Devices Market, 2016 – 2026: Optimistic Scenario (USD Billion)
Table 12.70 MIGS Devices Market, 2016 – 2026: Conservative Scenario (USD Billion)
Table 12.71 Non-MIGS Devices Market, 2016 – 2026: Base Scenario (USD Billion)
Table 12.72 Non-MIGS Devices Market, 2016 – 2026: Optimistic Scenario (USD Billion)
Table 12.73 Non-MIGS Devices Market, 2016 – 2026: Conservative Scenario (USD Billion)
Table 12.74 Non-MIGS Devices Market, 2026: Distribution by Device Category
Table 12.75 Glaucoma Therapies Market: Distribution by Treatment Modalities, 2016, 2021, and 2026 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report

  1.  AC Immune
  2.  ACADIA Pharmaceuticals
  3.  Acorn Biomedical
  4.  Actavis
  5.  Aerie Pharmaceuticals
  6.  Alcon Laboratories
  7.  Alcon Research
  8.  Allegro Investment Fun
  9.  Allergan
  10.  Allysta Pharmaceuticals
  11.  Alta Partners
  12.  Altacor
  13.  Amakem Therapeutics
  14.  Amgen
  15.  Amorphex Therapeutics
  16.  Amoun Pharmaceutical
  17.  AqueSys
  18.  Ascension Health Ventures
  19.  Ascension Ventures
  20.  AYUMI Pharmaceutical
  21.  Bascom Palmer Eye Institute
  22.  Bausch & Lomb
  23.  Bayer
  24.  Beaver-Visitec International
  25.  Belgian Investment Federal Fund
  26.  BioAxone BioSciences
  27.  Bio-Light Life Sciences
  28.  BioWin
  29.  Caisse de depot et placement du Quebec
  30.  Can-Fite BioPharma
  31.  Capricorn Health-Tech Fund NV
  32.  Care Capital
  33.  Clarus Ventures
  34.  Coherent
  35.  Coronis Partners
  36.  Cristalens
  37.  Crown Venture Fund
  38.  D. Western Therapeutics Institute
  39.  D.O.R.C. International
  40.  Deerfield Management Company
  41.  Delphi Ventures
  42.  Dendreon
  43.  Device Technologies
  44.  Devon Park Bioventures
  45.  EDBI
  46.  Ellex
  47.  Ellex iScience
  48.  Envisia Therapeutics
  49.  Ergo-Prevent
  50.  EVS Glaucoma Therapeutics
  51.  Eye Sonix
  52.  Eye Tech Care
  53.  Financière Spin-off Luxembourgeoise (INVESTSUD Group)
  54.  Fond Européen des Matériaux
  55.  Foresite Capital
  56.  Forest Laboratories
  57.  ForSight VISION5
  58.  Fuji Laboratory
  59.  GBS Ventures
  60.  GlaucoPharm
  61.  Glaukos
  62.  Glautec
  63.  Graybug Vision
  64.  Handok
  65.  Healionics Corporation
  66.  Hercules Technology Growth Capital
  67.  Hicks Equity Partners
  68.  Horizon Technology Finance Corporation
  69.  Hospital Clinico San Carlos
  70.  Hoya Group
  71.  Icon Bioscience
  72.  InMed Pharmaceuticals
  73.  InnFocus
  74.  Innovative Therapie und Diagnostik GmbH
  75.  Inotek Pharmaceuticals
  76.  InSite Vision
  77.  International Medical Distribution
  78.  InView Medical
  79.  IOPtima
  80.  Iridex Corporation
  81.  Isarna Therapeutics
  82.  iScience Interventional
  83.  Iskowitz Instrumental SRL
  84.  iSTAR Medical
  85.  Ivantis
  86.  Kadmon
  87.  Kala Pharmaceuticals
  88.  Kowa Company
  89.  Leo Lens Technology
  90.  Lexicon Pharmaceuticals
  91.  Makina Optik Ticaret
  92.  Marathon
  93.  Mati Therapeutics
  94.  McGee Eye Institute
  95.  MedImmune Ventures
  96.  Medisurg
  97.  Meditor Capital Management
  98.  MemorialCare Innovation Fund
  99.  Merck & Co.
  100. MicroOptx Medical
  101. Miller School of Medicine
  102. Mitsubishi UFJ Capital
  103. Namur Invest - Preface
  104. NEMUS Bioscience
  105. Neomedix
  106. New Enterprise Associates
  107. New World Medical
  108. NicOx
  109. Novaliq GmbH
  110. Novartis
  111. Ocular Therapeutix
  112. Oculis Pharma
  113. OftalMedica srl
  114. OHR Pharmaceutical
  115. Ono Pharmaceuticals
  116. OphthaliX
  117. Ophthalmos
  118. Osage University
  119. Otsuka Pharmaceutical
  120. Oxford BioMedica
  121. Palobiofarma
  122. Peregrine Ophthalmic
  123. Pfizer
  124. Pioneer Pharma
  125. Pitango Venture Capital
  126. New Enterprise Associates (NEA)
  127. Polyactiva
  128. pSivida
  129. Radikal Therapeutics
  130. Ramot at Tel Aviv University
  131. Regeneron
  132. Replenish
  133. Rheon Medical
  134. Rho Ventures
  135. Roche
  136. Rosellini Scientific Benelux
  137. Saints Capital Everest
  138. Salix
  139. Sanoculis
  140. Sanofi
  141. Santen Pharmaceutical  
  142. Scientific Health Development Partners
  143. Senju Pharmaceutical
  144. Shire
  145. Showa Yakuhin
  146. Sight Sciences
  147. Société Régionale d'Investissement de Wallonie (SRIW)
  148. Sofinnova Ventures
  149. SOLX
  150. STAAR Surgical
  151. Sun Pharma company
  152. Sylentis
  153. Technomix SA
  154. Tisbury Pharmaceuticals
  155. Tokyo New Drug Research Laboratories
  156. TPG Biotech
  157. Transcend Medical
  158. Ube Industries
  159. University of Miami
  160. University of Oklahoma
  161. University of Washington
  162. Valeant Pharmaceuticals International
  163. Vertex Ventures
  164. Wakamoto
  165. Yotsuya Shirato Eye Clinic

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com